Document is current

Article History

Received: 11 November 2025

Revised: 16 April 2026

Accepted: 15 May 2026

First Online: 20 June 2026

Competing interests

: MM is one of the Editors-in-Chief at Bone Marrow Transplantation and has received research funding and honoraria from Jazz Pharmaceuticals. RPdL, ML, and DB have received honoraria from Jazz Pharmaceuticals. VA, AP, DG, and ND are employees of Jazz Pharmaceuticals and hold stock and/or stock options in Jazz Pharmaceuticals. HL-W has nothing to disclose.

: The DEFIFrance study was conducted in compliance with the ethical principles defined in the Declaration of Helsinki and according to Good Epidemiological Practice defined by ADELF (Association Des Epidémiologistes de Langue Française—Association of French-language Epidemiologists) and current legislation. Written informed consent was obtained from the patient or the patient’s legal guardian. Data from deceased patients were included if the patient did not express opposition to the collection of their data while they were alive. The EBMT PASS study was conducted in compliance with Good Epidemiology Practice guidelines, principles of the Declaration of Helsinki and current local regulations. All patients provided written informed consent for personal and medical data collection.

: MM is one of the Editors-in-Chief at Bone Marrow Transplantation and has received research funding and honoraria from Jazz Pharmaceuticals. RPdL, ML, and DB have received honoraria from Jazz Pharmaceuticals. VA, AP, DG, and ND are employees of Jazz Pharmaceuticals and hold stock and/or stock options in Jazz Pharmaceuticals. HL-W has nothing to disclose.